Guilherme Harada: Honored to Have Contributed to This Study
Guilherme Harada, Medical Oncologist at Hospital Sírio-Libanês, shared JTO & JTO CRR’s post on X:
“Honored to have contributed to this study
Due to its alternative type II binding mode and its broad availability, cabozantinib can be particularly useful in the treatment of resistance to type I MET TKIs.”
Quoting JTO & JTO CRR’s post:
“In this phase II trial evaluating the activity of cabozantinib, Harada et al. demonstrated that this treatment could benefit patients with MET-altered lung cancers previously treated with type I MET TKIs.
Title: A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers
Authors: Guilherme Harada, Fernando C. Santini, Clare J. Wilhelm, Rebecca W. Repetti, Jason C. Chang, Soo-Ryum Yang, Yun-Te Lin, Khadeja A. Moses, Christina Falcon, Michelle Goldstein, Alex Makhnin, Michelle S. Ginsberg, Andrew J. Plodkowski, Mark G. Kris, Alexander Drilon
More posts featuring Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023